Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Artigo
|
Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trialEarl, Helena M, Dr ; Vallier, Anne-Laure, MSc ; Hiller, Louise, Dr ; Fenwick, Nicola, BSc ; Young, Jennie, BSc ; Iddawela, Mahesh, MBBS ; Abraham, Jean, MBBS ; Hughes-Davies, Luke, MBBCh ; Gounaris, Ioannis, MD ; McAdam, Karen, MBBS ; Houston, Stephen, MBBS ; Hickish, Tamas, MBBS ; Skene, Anthony, MBBS ; Chan, Stephen, MBBCh ; Dean, Susan, MBBS ; Ritchie, Diana, MBBS ; Laing, Robert, MBBS ; Harries, Mark, MBBCh ; Gallagher, Christopher, MBBS ; Wishart, Gordon, Prof ; Dunn, Janet, Prof ; Provenzano, Elena, MD ; Caldas, Carlos, ProfThe lancet oncology, 2014-02, Vol.15 (2), p.201-212 [Periódico revisado por pares]England: Elsevier LtdTexto completo disponível |
|
2 |
Material Type: Artigo
|
Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2x2 factorial randomised phase 3 trialEarl, Helena M ; Vallier, Anne-Laure ; Hiller, Louise ; Fenwick, Nicola ; Young, Jennie ; Iddawela, Mahesh ; Abraham, Jean ; Hughes-Davies, Luke ; Gounaris, Ioannis ; McAdam, Karen ; Houston, Stephen ; Hickish, Tamas ; Skene, Anthony ; Chan, Stephen ; Dean, Susan ; Ritchie, Diana ; Laing, Robert ; Harries, Mark ; Gallagher, Christopher ; Wishart, Gordon ; Dunn, Janet ; Provenzano, Elena ; Caldas, CarlosThe lancet oncology, 2014-02, Vol.15 (2), p.201-212 [Periódico revisado por pares]Texto completo disponível |
|
3 |
Material Type: Artigo
|
Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trialEarl, Helena M, Professor ; Hiller, Louise, PhD ; Howard, Helen C, PhD ; Dunn, Janet A, Prof ; Young, Jennie, BA ; Bowden, Sarah J, PhD ; McDermaid, Michelle ; Waterhouse, Anna K, BSc ; Wilson, Gregory, FRCP ; Agrawal, Rajiv, FRCR ; O'Reilly, Susan, MD ; Bowman, Angela, MB ChB ; Ritchie, Diana M, MD ; Goodman, Andrew, MB ChB ; Hickish, Tamas, Prof ; McAdam, Karen, FRCP ; Cameron, David, Prof ; Dodwell, David, Prof ; Rea, Daniel W, FRCP ; Caldas, Carlos, Prof ; Provenzano, Elena, PhD ; Abraham, Jean E, PhD ; Canney, Peter, MD ; Crown, John P, Prof ; Kennedy, M John, Prof ; Coleman, Robert, Prof ; Leonard, Robert C, Prof ; Carmichael, James A, MD ; Wardley, Andrew M, Prof ; Poole, Christopher J, ProfThe lancet oncology, 2017-06, Vol.18 (6), p.755-769 [Periódico revisado por pares]England: Elsevier LtdTexto completo disponível |